-

Monte Rosa Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics, a biotechnology company focused on developing precision medicines to degrade disease-causing proteins, today announced it is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021, at 11:00 a.m. ET. Markus Warmuth, M.D., CEO of Monte Rosa, will be presenting a corporate overview followed by a Q&A session.

About Monte Rosa

Monte Rosa Therapeutics is a biotechnology company developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland. For more information, visit www.monterosatx.com.

Contacts

Dan Budwick
1AB Media
dan@1abmedia.com

Monte Rosa


Release Summary
Monte Rosa Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
Release Versions

Contacts

Dan Budwick
1AB Media
dan@1abmedia.com

Social Media Profiles
More News From Monte Rosa

Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer

BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics Expands Leadership Team with Appointment of Filip Janku, M.D., Ph.D., as Chief Medical Officer...

Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform

BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform...

Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments

BOSTON--(BUSINESS WIRE)--Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments...
Back to Newsroom